Published in Endocr Connect on April 29, 2016
Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet (2000) 4.34
Premature mortality due to cardiovascular disease in hypopituitarism. Lancet (1990) 2.92
Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab (1991) 2.27
Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom (2014) 1.89
Association between bone density and fractures in children: a systematic review and meta-analysis. Pediatrics (2006) 1.69
Cortical bone density is normal in prepubertal children with growth hormone (GH) deficiency, but initially decreases during GH replacement due to early bone remodeling. J Clin Endocrinol Metab (2003) 1.57
The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab (2003) 1.44
The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. . J Bone Miner Res (2001) 1.32
Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom (2014) 1.21
Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10-24 years of age. Osteoporos Int (1996) 1.12
Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab (1993) 1.09
Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol (1997) 1.09
Risk factors for fractures in normally active children and adolescents. Med Sport Sci (2007) 1.06
Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol (Oxf) (2009) 0.98
Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J Bone Miner Res (2007) 0.97
Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program. J Clin Endocrinol Metab (2011) 0.95
Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab (2003) 0.94
Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency. J Clin Endocrinol Metab (2010) 0.91
Quality of life of growth hormone (GH) deficient young adults during discontinuation and restart of GH therapy. Psychoneuroendocrinology (2003) 0.91
Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Horm IGF Res (2005) 0.90
Mortality and GH deficiency: a nationwide study. Eur J Endocrinol (2007) 0.89
Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab (2004) 0.88
Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab (2005) 0.87
A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. J Clin Endocrinol Metab (2005) 0.86
Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab (2004) 0.86
Cognition in the adult with childhood-onset GH deficiency. Eur J Endocrinol (2008) 0.86
Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol (2009) 0.86
GH is needed for the maturation of muscle mass and strength in adolescents. J Clin Endocrinol Metab (2001) 0.85
Impact of growth hormone (GH) therapy on quality of life along the lifespan of GH-treated patients. Horm Res (2001) 0.85
Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. J Clin Endocrinol Metab (2006) 0.85
Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism. J Clin Endocrinol Metab (2000) 0.85
A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis. Eur J Endocrinol (2012) 0.85
The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab (2002) 0.84
Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol (Oxf) (2004) 0.84
Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol (2013) 0.84
The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab (1996) 0.83
Common carotid intima-media thickness in growth hormone (GH)-deficient adolescents: a prospective study after GH withdrawal and restarting GH replacement. J Clin Endocrinol Metab (2005) 0.83
Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab (2003) 0.83
Changes in body composition and bone density after discontinuation of growth hormone therapy in adolescence: an interim report. Acta Paediatr Suppl (1994) 0.82
Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency. Horm Res (2009) 0.82
Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab (2001) 0.82
Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab (2004) 0.82
Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age. Am Heart J (2003) 0.81
Subtle alterations of cardiac performance in children with growth hormone deficiency: results of a two-year prospective, case-control study. J Clin Endocrinol Metab (2009) 0.81
Quality of life and retrospective perception of the effect of growth hormone treatment in adult patients with childhood growth hormone deficiency. J Pediatr Endocrinol Metab (2001) 0.81
Quality of life in childhood onset growth hormone-deficient patients in the transition phase from childhood to adulthood. J Clin Endocrinol Metab (2005) 0.81
Lumbar bone mineral density at final height and prevalence of fractures in treated children with GH deficiency. J Clin Endocrinol Metab (2002) 0.80
A study of carotid intima-media thickness in GH-deficient Japanese adults during onset among adults and children. Eur J Endocrinol (2003) 0.79
Effects of growth hormone (GH) therapy withdrawal on glucose metabolism in not confirmed GH deficient adolescents at final height. PLoS One (2014) 0.79
Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab (1999) 0.78
Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency. Osteoporos Int (2011) 0.78
Update on early cardiovascular and metabolic risk factors in children and adolescents affected with growth hormone deficiency. Minerva Endocrinol (2012) 0.78
Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults. Clin Endocrinol (Oxf) (1991) 0.78
An audit of growth hormone replacement for GH-deficient adults in Scotland. Clin Endocrinol (Oxf) (2013) 0.78
A prospective investigation of quality of life and psychological well-being after the discontinuation of GH treatment in adolescent patients who had GH deficiency during childhood. J Clin Endocrinol Metab (2001) 0.78
Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab (2000) 0.78
Early changes in body composition after cessation of growth hormone therapy in childhood-onset growth hormone deficiency. J Clin Densitom (2011) 0.76
GH deficiency during the transition period: clinical characteristics before and after GH replacement therapy in two different subgroups of patients. J Pediatr Endocrinol Metab (2012) 0.76
Is GH therapy useful to preserve bone mass in transition-phase patients with GH deficiency? J Endocrinol Invest (2005) 0.76
Muscle strength and body composition during the transition phase in patients treated with recombinant GH to final height. J Pediatr Endocrinol Metab (2014) 0.76
Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents. Clin Endocrinol (Oxf) (2001) 0.76
MRI-based abnormalities in young adults at risk of adverse bone health due to childhood-onset metabolic & endocrine conditions. Clin Endocrinol (Oxf) (2013) 0.76